Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy

被引：73

作者：

Rudas, Margaretha ^{[2
]}

Lehnert, Martina ^{[1
]}

Huynh, Anh

Jakesz, Raimund ^{[3
]}

Singer, Christian ^{[4
]}

Lax, Sigurd

Schippinger, Walter ^{[7
]}

Dietze, Otto ^{[9
]}

Greil, Richard ^{[8
]}

Stigibauer, Wolfgang ^{[11
]}

Kwasny, Werner ^{[10
]}

Grill, Renate ^{[5
]}

Stierer, Michael ^{[6
]}

Gnant, Michael F. X. ^{[3
]}

Filipits, Martin ^{[1
]}

机构：

[1] Med Univ Vienna, Inst Canc Res, Dept Med 1, A-1090 Vienna, Austria

[2] Med Univ Vienna, Dept Pathol, A-1090 Vienna, Austria

[3] Med Univ Vienna, Dept Surg, A-1090 Vienna, Austria

[4] Med Univ Vienna, Dept Special Gynecol, A-1090 Vienna, Austria

[5] Hanusch Med Ctr, Dept Pathol & Microbiol, Vienna, Austria

[6] Hanusch Med Ctr, Dept Surg, Vienna, Austria

[7] Med Univ Graz, Dept Internal Med, Graz, Austria

[8] Paracelsus Private Med Univ, Gen Hosp Salzburg, Dept Internal Med 3, Salzburg, Austria

[9] Paracelsus Private Med Univ, Gen Hosp Salzburg, Dept Pathol, Salzburg, Austria

[10] Gen Hosp Wiener Neustadt, Dept Surg, Wiener Neustadt, Austria

[11] Gen Hosp Wiener Neustadt, Inst Pathol, Wiener Neustadt, Austria

来源：

CLINICAL CANCER RESEARCH | 2008年 / 14卷 / 06期

关键词：

D O I：

10.1158/1078-0432.CCR-07-4122

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifenbased therapy. Experimental Design: We assessed expression of cyclin D1 in surgical specimens of breast carcinoma by means of immunohistochemistry. Patients had been enrolled in either Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 05 or ABCSG Trial 06 and received tamoxifen as part of their adjuvant treatment. Overall survival and relapse-free survival were analyzed with Cox models adjusted for clinical and pathologic factors. Results: Cyclin D1 was expressed in 140 of 253 (55%) tumors of ABCSG Trial 05 and in 569 of 948 (60%) tumors of ABCSG Trial 06. Expression of cyclin D1 was associated with poor outcome in both cohorts. Overall survival was significantly shorter in patients with cyclin D1 - positive tumors compared with patients with cyclin D1 - negative tumors [adjusted hazard ratio (HR) for death (ABCSG Trial 05), 2.47; 95% confidence interval (95% Cl), 1.08-5.63; P = 0.03; adjusted HR for death (ABCSG Trial 06),1.78; 95% Cl, 1.36-2.34; P < 0.0001]. Relapse-free survival was also shorter in patients with cyclin D1 - positive tumors than in patients with cyclin D1 - negative tumors [adjusted HR for relapse (ABCSG Trial 05), 2.73; 95% Cl, 1.50-4.96; P = 0.001; adjusted HR for relapse (ABCSG Trial 06),1.52; 95% Cl, 1.14-2.04; P = 0.0051. Conclusion: Cyclin D1 expression is an independent poor prognostic factor in women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen-based therapy.

引用

页码：1767 / 1774

页数：8

共 32 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2] Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance [J].

Ahnström, M ;

Nordenskjöld, B ;

Rutqvist, LE ;

Skoog, L ;

Stål, O .

BREAST CANCER RESEARCH AND TREATMENT, 2005, 91 (02) :145-151

[3] Cyclin D1 in breast cancer pathogenesis [J].

Arnold, A ;

Papanikolaou, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4215-4224

[4] Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells [J].

Bindels, EMJ ;

Lallemand, F ;

Balkenende, A ;

Verwoerd, D ;

Michalides, R .

ONCOGENE, 2002, 21 (53) :8158-8165

[5]

BUCKLEY MF, 1993, ONCOGENE, V8, P2127

[6] Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E [J].

Butt, AJ ;

McNeil, CM ;

Musgrove, EA ;

Sutherland, RL .

[7]

Clarke R, 2001, PHARMACOL REV, V53, P25

[8] Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study [J].

Coleman, Robert E. ;

Banks, Linda M. ;

Girgis, Samia I. ;

Kilburn, Lucy S. ;

Vrdoljak, Eduard ;

Fox, John ;

Cawthorn, Simon J. ;

Patel, Ashraf ;

Snowdon, Claire F. ;

Hall, Emma ;

Bliss, Judith M. ;

Coombes, R. Charles .

LANCET ONCOLOGY, 2007, 8 (02) :119-127

[9] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J].

Coombes, R. C. ;

Kilburn, L. S. ;

Snowdon, C. F. ;

Paridaens, R. ;

Coleman, R. E. ;

Jones, S. E. ;

Jassem, J. ;

Van de Velde, C. J. H. ;

Delozier, T. ;

Alvarez, I. ;

Del Mastro, L. ;

Ortmann, O. ;

Diedrich, K. ;

Coates, A. S. ;

Bajetta, E. ;

Holmberg, S. B. ;

Dodwell, D. ;

Mickiewicz, E. ;

Andersen, J. ;

Lonning, P. E. ;

Cocconi, G. ;

Forbes, J. ;

Castiglione, M. ;

Stuart, N. ;

Stewart, A. ;

Fallowfield, L. J. ;

Bertelli, G. ;

Hall, E. ;

Bogle, R. G. ;

Carpentieri, M. ;

Colajori, E. ;

Subar, M. ;

Ireland, E. ;

Bliss, J. M. .

LANCET, 2007, 369 (9561) :559-570

[10] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].

Coombes, RC ;

Hall, E ;

Gibson, LJ ;

Paridaens, R ;

Jassem, J ;

Delozier, T ;

Jones, SE ;

Alvarez, I ;

Bertelli, G ;

Ortmann, O ;

Coates, AS ;

Bajetta, E ;

Dodwell, D ;

Coleman, RE ;

Fallowfield, LJ ;

Mickiewicz, E ;

Andersen, J ;

Lonning, PE ;

Cocconi, G ;

Stewart, A ;

Stuart, N ;

Snowdon, CF ;

Carpentieri, M ;

Massimini, G ;

Bliss, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092

← 1 2 3 4 →